Nitazoxanide: a new broad spectrum antiparasitic agent

@article{WhiteJr2004NitazoxanideAN,
  title={Nitazoxanide: a new broad spectrum antiparasitic agent},
  author={A. Clinton White Jr.},
  journal={Expert Review of Anti-infective Therapy},
  year={2004},
  volume={2},
  pages={43 - 49}
}
  • A. C. White Jr.
  • Published 1 February 2004
  • Medicine, Biology
  • Expert Review of Anti-infective Therapy
Nitazoxanide (Alinia®, Romark Laboratories) was synthesized based on the structure of niclosamide. In vitro studies have demonstrated activity against a broad range of parasites as well as some bacteria. Three controlled trials demonstrated efficacy in cryptosporidiosis, however, the efficacy in advanced AIDS patients (CD4 cell counts = 50) at approved doses was limited. Trials have also demonstrated efficacy comparable to metronidazole (Flagyl®, GD Searle and Co.) in giardiasis with fewer side… 

Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways

For the first time, antagonists of TMEM16A and repositioning of niclosamide and nitazoxanide represent an important additional treatment for patients with severe asthma and COPD that is poorly controlled with existing therapies.

Structure-Activity Study of Nitazoxanide Derivatives as Novel STAT3 Pathway Inhibitors.

A broad-spectrum effect of these thiazolides as antitumor agents targeted on STAT3 is indicated, indicating a broad-Spectrum effect on the effectiveness of theseThiazolide scaffold as anti-cancer agents.

COVID-19 Therapeutic Options Under Investigation

A review of the potential therapeutic agents being considered for the treatment and management of COVID-19 patients and two compounds, remdesivir, and dexamethasone have been so far shown to reduce CO VID-19–associated death.

Nanodelivery of nitazoxanide: impact on the metabolism of Taenia crassiceps cysticerci intracranially inoculated in mice.

The remarkable metabolic modifications that occur in this in vivo model through the application of these developed nanosystems confirm their capability to deliver NTZ into targeted tissues.

Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis

NTZ could inhibit osteoclastogenesis and bone loss through modulation of the receptor activator of NF-κB ligand-induced STAT3-NFATc1 signaling pathway, which might be a potential alternative treatment regimen against bone destruction-related diseases including osteoporosis.

Synthetic antiprotozoal thiazolide drug induced apoptosis in colorectal cancer cells: implications of IL-6/JAK2/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro study

Novel evidence is provided that NTZ could be a dual potential IL6/JAK2/STAT3 signaling inhibitor and p53/caspases-dependent pathway activator in CRC cell line, and this potentials support further exploratory molecular researches targeting the therapeutic roles of NTZ in CRC.

Antiviral drugs and plasma therapy used for Covid-19 treatment: a nationwide Turkish algorithm

It was aimed to discuss that Covidien-19 against antiviral drugs used in the struggle across the globe and plasma treatment options about the current state of knowledge and Turkey algorithm by comparing the therapeutic treatment options.

Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities

Significant advances have been made in areas of diagnostic and therapeutic modalities, with an increasing number of potential drugs currently in phase II and III trials, particularly in the field of non-alcoholic steatohepatitis-related liver fibrosis.

References

SHOWING 1-10 OF 19 REFERENCES

Nitazoxanide: an important advance in anti-parasitic therapy.

  • A. White
  • Medicine
    The American journal of tropical medicine and hygiene
  • 2003
The development of nitazoxanide was originally discovered in the 1980s by Jean Francois Rossignol at the Pasteur Institute and focused on development of the drug for treatment of cryptosporidiosis in acquired immunodeficiency syndrome.

Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections.

Nitazoxanide, a nitrothiazole derivative, was tested in patients infected with Taenia saginata and 18 infected with Hymenolepis nana and tolerance of the drug was good at both dose levels used.

Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico.

Case report: Nitazoxanide treatment failure in chronic isosporiasis.

Patients with malabsorption and cholangitis due to Coccidia such as Isospora belli and Cryptosporidium spp.

In Vitro Parasiticidal Effect of Nitazoxanide against Echinococcus multilocularis Metacestodes

The in vitro parasiticidal effect of nitazoxanide (NTZ), a broad-spectrum drug used against intestinal parasites and bacteria, was investigated and showed that in vitro treatment of E. multilocularis metacestodes with NTZ induced high levels of alkaline phosphatase activity in the medium.

Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model.

Nitazoxanide (NTZ) was compared for curative activity with sinefungin (SNF) and paromomycin (PRM) in immunosuppressed rats, a screening model for anticryptosporidial agents and shedding inhibition was unchanged in NTZ-treated rats.

Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico.

Nitazoxanide was very well tolerated, with no serious adverse effects reported, in the treatment of mixed parasite infections with both intestinal protozoa and helminths in children.

The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection.

Triclabendazole 20 mg/kg is an effective therapy for the treatment of F. hepatica infection in patients who have failed to respond to other antihelminthic agents.

Successful Treatment with Nitazoxanide of Enterocytozoon bieneusi Microsporidiosis in a Patient with AIDS

ABSTRACT A patient with AIDS and chronic diarrhea caused byEnterocytozoon bieneusi was successfully treated with nitazoxanide, producing a complete clinical and parasitological response, while off of